Editas Medicine

EDIT · NASDAQ

$2.58+$0.16 (+6.61%)TodayMarket closed · Oct 20, 7:51 PM ET

Prev close $2.42

EDIT analyst rating

BuyConsensus of 5 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy5
Hold0
Underperform0
Sell0

12-month price target · 10 analysts

Average $6.12 (+137.2% upside)

Low: $1.01
Now: $2.58
High: $15.75

Upgrades and downgrades

The latest rating actions, newest first

EDIT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wells Fargo	Oct 8, 2026	Upgrade	Equal-Weight → Overweight	$4.00 → $6.00	32%
Guggenheim	Sep 23, 2026	Upgrade	Neutral → Buy	$5.00	45%
Ladenburg Thalmann	Aug 18, 2026	Initiates	Buy	$6.00	—
Chardan Capital	May 5, 2026	Maintains	Buy	$3.50 → $4.00	43%
Jones Trading	Mar 10, 2026	Upgrade	Hold → Buy	$8.00	31%
Chardan Capital	Mar 9, 2026	Maintains	Buy	$3.50	43%

The case for and against

Updated Oct 16, 2026

Bull case

Editas Medicine is viewed positively because EDIT-401 appears to offer a differentiated, one-time CRISPR approach that could drive very deep lipid reductions, with preclinical data showing >90% LDL-C and >70% ApoB lowering and additional evidence of Lp(a) reduction in NHPs. The investment case is strengthened by a favorable regulatory and clinical backdrop, including the 13 March 2026 ACC/AHA guideline’s renewed emphasis on explicit LDL-C goals, universal Lp(a) screening, and early potent intervention, which could expand demand for transformative ASCVD therapies. Financially, the company reported $123.6 million in cash and equivalents as of 31 March 2026, implying runway into 3Q27, while modeled risk-adjusted 2035E sales of $515.5 million support meaningful long-term upside if clinical proof of concept is confirmed.

Bear case

Editas Medicine is viewed negatively because its core programs still face substantial clinical uncertainty, including first-in-human risks for EDIT-401, limited human data for dual guideRNA editing, and the possibility that efficacy seen in animals will not translate to patients. Although EDIT-401 showed about 49% LDL-C and 55% TG reduction at the highest dose and favorable liver tolerance in NHPs, the company still has to prove durable safety, manage off-target and extrahepatic editing risk, and demonstrate real-world demand in HeFH/ASCVD. The investment case is further weakened by regulatory and commercialization uncertainty, potential IP issues, and the likely need for additional capital that could dilute shareholders before profitability.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.